Developing alternative routes of administration for needle-free delivery.

Our research demonstrates that intranasal administration of vaccines based on our platforms delivers strong mucosal immune responses, enhancing protection from respiratory diseases and potentially eliminating the need for needles.

  • AAHI’s dual agonist liposomal formulation combined with a protein antigen is safe and immunogenic when administered intranasally and shows protective efficacy against COVID and Amebiasis.
  • Based on the promising results of preclinical studies of our intranasal COVID saRNA vaccine candidate, BARDA is funding further collaboration to establish proof-of-concept for a dry powder, intranasally delivered (inhalable) saRNA vaccine for pandemic influenza.